137 related articles for article (PubMed ID: 37037186)
21. Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects.
Harada A; Ikushima I; Haranaka M; Yanagihara A; Nakayama D
Am J Cardiovasc Drugs; 2020 Jun; 20(3):249-258. PubMed ID: 31667735
[TBL] [Abstract][Full Text] [Related]
22. In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically Based Absorption Models.
Sjögren E; Thörn H; Tannergren C
Mol Pharm; 2016 Jun; 13(6):1763-78. PubMed ID: 26926043
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
Sikes C; Stark JG; McMahen R; Engelking D
Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
[TBL] [Abstract][Full Text] [Related]
24. Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling.
Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
Eur J Pharm Sci; 2021 Mar; 158():105656. PubMed ID: 33253885
[TBL] [Abstract][Full Text] [Related]
25. Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.
Faber KP; Wu HF; Yago MR; Xu X; Kadiyala P; Frassetto LA; Benet LZ
Pharm Res; 2017 Mar; 34(3):619-628. PubMed ID: 28028768
[TBL] [Abstract][Full Text] [Related]
26. Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.
Sun W; Klamerus KJ; Yuhas LM; Pawlak S; Plotka A; O'Gorman M; Kirkovsky L; Kosa M; Wang D
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):614-626. PubMed ID: 28430398
[TBL] [Abstract][Full Text] [Related]
27. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
28. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
[TBL] [Abstract][Full Text] [Related]
29. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 2: Fed State.
Paixão P; Bermejo M; Hens B; Tsume Y; Dickens J; Shedden K; Salehi N; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Wysocki J; Wen B; Lee A; Frances A; Amidon GE; Yu A; Benninghoff G; Löbenberg R; Talattof A; Sun D; Amidon GL
Mol Pharm; 2018 Dec; 15(12):5468-5478. PubMed ID: 30417648
[TBL] [Abstract][Full Text] [Related]
30. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
[TBL] [Abstract][Full Text] [Related]
31. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
32. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
33. Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound.
Xia B; Heimbach T; Lin TH; Li S; Zhang H; Sheng J; He H
AAPS PharmSciTech; 2013 Sep; 14(3):1255-66. PubMed ID: 23955148
[TBL] [Abstract][Full Text] [Related]
34. Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations.
Schick P; Sager M; Voelker M; Weitschies W; Koziolek M
Eur J Pharm Biopharm; 2020 Jun; 151():9-17. PubMed ID: 32268191
[TBL] [Abstract][Full Text] [Related]
35. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
36. The effect of food and acid-reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study.
Miller C; Sommavilla R; Murphy D; Morris T; Khatun M; Cullberg M
Br J Clin Pharmacol; 2023 Nov; 89(11):3330-3339. PubMed ID: 37328269
[TBL] [Abstract][Full Text] [Related]
37. Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface.
Dodd S; Kollipara S; Sanchez-Felix M; Kim H; Meng Q; Beato S; Heimbach T
J Pharm Sci; 2019 Jan; 108(1):87-101. PubMed ID: 30385285
[TBL] [Abstract][Full Text] [Related]
38. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
39. Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects.
Qian H; Fan S; Li K; Sai Y; Su W; Chen Q; Liu Y; Li T; Wang W; Jia J; Yu C; Liu Y
Clin Ther; 2019 Aug; 41(8):1537-1544. PubMed ID: 31272709
[TBL] [Abstract][Full Text] [Related]
40. Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect.
Zhang H; Xia B; Sheng J; Heimbach T; Lin TH; He H; Wang Y; Novick S; Comfort A
AAPS PharmSciTech; 2014 Apr; 15(2):400-6. PubMed ID: 24435225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
